Envision Pharma Group acquires doDOC to enable seamless document collaboration as part of iEnvision, its global medical affairs platform
22 March 2021
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Envision Pharma Group, regarding the acquisition of doDOC.
Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring.
doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today.
While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC.
Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi.
David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.”
“Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.”
Manish Goel, Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.”
– Ends –
GHO Capital Partners LLP
T +44 20 3700 7440
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare . For further information, please visit www.ghocapital.com.
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies.
Envision has 20 offices: seven in the United Kingdom – Bishop’s Stortford, Glasgow, Horsham, London (Battersea and Hammersmith), Wilmslow, and Alderley Edge; one in Serbia – Subotica; one in Hungary – Szeged; one in Coimbra, Portugal, eight in the United States – Fairfield and Glastonbury, CT, Philadelphia and Wyomissing, PA, Warren, NJ, Boston and Melrose, MA, Powell, OH; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs over 1000 team members, including over 250 highly qualified and experienced in-house medical writers, and 190 technology solutions team members who provide software development and customer support. For further information, please visit www.envisionpharmagroup.com.
Founded by MIT alumni in 2015 in Boston, MA, and with a European base in Coimbra, doDOC has the mission to transform the way life sciences teams write and review their documents, offering cloud-based software for enterprise documentation.
By giving teams the power to control permissions on a granular level, have full traceability on edits and comments, automate tasks, and benefit from flexible integrations that build on top of existing systems, doDOC helps cut more than 70% of the time needed to write and review a document.
The company serves enterprise clients in diverse industries, with its main focus on pharmaceutical and biotechnology companies. It currently works with top pharmaceutical companies worldwide, with the best examples in medical, scientific, regulatory, and legal writing. For further information, please visit www.dodoc.com.